Anti-PCSK9 Antibody Formulation for Statin-Resistant LDL-C Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypercholesterolemia, such as statin therapy, are inadequate for some patients, and there is a need for novel therapies that can more effectively reduce LDL-C levels and address cholesterol-related disorders.
Innovation Solution
Administration of anti-PCSK9 antibodies in varying doses and schedules to lower serum LDL cholesterol, PCSK9 values, total cholesterol, non-HDL cholesterol, ApoB levels, and Lp(a) levels, thereby treating or preventing cholesterol-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to treat hypercholesterolemia, then LDL-C levels are reduced, but the treatment is not effective for all patients and some patients are intolerant or do not respond adequately
Solution Approach 1:
The patent introduces PCSK9 as an intermediary target in the cholesterol metabolism pathway. By developing monoclonal antibodies against PCSK9, the invention creates a new therapeutic mechanism that indirectly enhances LDL receptor activity and LDL-C clearance, bypassing the limitations of direct HMG-CoA reductase inhibition by statins.
Solution Approach 2:
The patent changes the therapeutic parameter from inhibiting HMG-CoA reductase (statin mechanism) to inhibiting PCSK9 (monoclonal antibody mechanism). This parameter change in the molecular target allows for a different mode of action that can achieve greater LDL-C reduction and overcome statin intolerance or resistance in certain patient populations.
2Reliability
If more aggressive treatment is used to lower LDL-C levels, then cardiovascular risk is reduced, but the complexity of treatment options increases
Solution Approach 1:
The patent extracts the PCSK9 protein from the complex cholesterol metabolism system and targets it specifically with monoclonal antibodies. This extraction approach simplifies the therapeutic mechanism by focusing on a single key regulator (PCSK9) that controls LDL receptor degradation, thereby achieving aggressive LDL-C lowering through a targeted rather than multifactorial approach.
3Quantity of substance
If PCSK9 activity is inhibited to lower LDL-C levels, then serum LDL cholesterol is reduced by up to 90%, but the mechanism involves complex protein-protein interactions
Solution Approach 1:
The monoclonal antibody serves as an intermediary that binds to PCSK9 and prevents its interaction with the LDL receptor. This intermediary approach simplifies the therapeutic strategy by using a standardized antibody molecule to block the harmful protein-protein interaction between PCSK9 and LDLR, achieving substantial LDL-C reduction without requiring direct manipulation of the complex endogenous protein interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-PCSK9 antibodies significantly reduce LDL cholesterol by 30-90%, PCSK9 by 60-90%, total cholesterol by 20-60%, non-HDL cholesterol by 30-85%, ApoB by 20-75%, and Lp(a) by 10-65%, providing effective treatment for hypercholesterolemia, hyperlipidemia, and dyslipidemia.
Implementation Method 1
administering anti-PCSK9 antibodies to inhibit the activity of proprotein convertase subtilisin/kexin type 9 (PCSK9)
Data Source
AI summary
The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.